共 86 条
Asthma in the era of COVID-19
被引:10
作者:
Assaf, Sara
[1
]
Stenberg, Henning
[2
]
Jesenak, Milos
[3
,4
]
Tarasevych, Svitlana P.
[5
]
Hanania, Nicola A.
[6
]
Diamant, Zuzana
[7
,8
,9
,10
,11
]
机构:
[1] Univ New Mexico, Sect Pulm & Crit Care Med, Albuquerque, NM 87131 USA
[2] Lund Univ, Ctr Primary Hlth Care Res, Malmo, Sweden
[3] Comenius Univ, Univ Teaching Hosp, Jessenius Fac Med Martin, Dept Pulmonol & Phthisiol, Martin, Slovakia
[4] Comenius Univ, Univ Teaching Hosp Martin, Dept Paediat, Dept Clin Immunol & Allergol,Jessenius Fac Med Mar, Martin, Slovakia
[5] Zaans Med Ctr, Dept Resp Med, Zaandam, Netherlands
[6] Baylor Coll Med, Sect Pulm & Crit Care Med, Houston, TX USA
[7] Katholieke Univ Leuven, Dept Microbiol & Immunol, Catholic Univ Leuven, Louvain, Belgium
[8] Lund Univ, Skane Univ Hosp, Dept Resp Med & Allergol, Inst Clin Sci, Lund, Sweden
[9] Charles Univ Prague, Fac Med 1, Dept Resp Med, Prague, Czech Republic
[10] Thomayer Hosp, Prague, Czech Republic
[11] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
关键词:
Asthma;
COVID-19;
Long COVID;
Phenotypes;
Biologicals;
BRONCHIAL EPITHELIAL-CELLS;
RISK;
RHINOVIRUS;
EXPRESSION;
SARS-COV-2;
HOSPITALIZATION;
EXACERBATIONS;
INFECTIONS;
RECEPTOR;
D O I:
10.1016/j.rmed.2023.107373
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Since its global invasion in 2019, COVID-19 has affected several aspects of patients' lives and posed a significant impact on the health care system. Several patient populations were identified to be at high risk of contracting SARS-CoV-2 infection and/or developing severe COVID-19-related sequelae. Conversely, anyone who has contracted SARS-CoV-2 is at risk to experience symptoms and signs consistent with post-COVID manifestations. Patients with asthma were initially thought to be at increased risk and severity for SARS-CoV-2 infection. However, accumulating evidence demonstrates that asthma endotypes/phenotypes and comorbidities influence the risk stratification in this population. Furthermore, initial concerns about the potentially increased risk of poor outcomes with asthma treatments such as inhaled corticosteroids and biologics have not been substantiated. In this review, we provide an update on COVID-19 and asthma, including risk of susceptibility, clinical manifestations and course in this population as well as discuss recommendations for management.
引用
收藏
页数:6
相关论文